Cargando…

Lipoatrophy/lipohypertrophy outcomes after antiretroviral therapy switch in children in the UK/Ireland

BACKGROUND: Following widespread use of stavudine, a thymidine analogue, in antiretroviral therapy (ART) over the past three decades, up to a third of children developed lipoatrophy (LA) and/or lipohypertrophy (LH). Following phasing-out of stavudine, incidence of newly-diagnosed LA and LH declined...

Descripción completa

Detalles Bibliográficos
Autores principales: Innes, Steve, Harvey, Justin, Collins, Intira Jeannie, Cotton, Mark Fredric, Judd, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884482/
https://www.ncbi.nlm.nih.gov/pubmed/29617438
http://dx.doi.org/10.1371/journal.pone.0194132
_version_ 1783311830451486720
author Innes, Steve
Harvey, Justin
Collins, Intira Jeannie
Cotton, Mark Fredric
Judd, Ali
author_facet Innes, Steve
Harvey, Justin
Collins, Intira Jeannie
Cotton, Mark Fredric
Judd, Ali
author_sort Innes, Steve
collection PubMed
description BACKGROUND: Following widespread use of stavudine, a thymidine analogue, in antiretroviral therapy (ART) over the past three decades, up to a third of children developed lipoatrophy (LA) and/or lipohypertrophy (LH). Following phasing-out of stavudine, incidence of newly-diagnosed LA and LH declined dramatically. However, the natural history of existing cases should be explored, particularly with prolonged protease inhibitor exposure. METHODS: The Collaborative HIV Paediatric Study (CHIPS) is a multicentre cohort study of most HIV-infected children in the United Kingdom and Ireland. Those on ART with a LA/LH assessment recorded in 2003–2011 were included. Assessments were completed annually by consultant physicians. Using the 0–3 grading system, LA or LH was defined as grade 2 or 3. Resolution was defined as return to grade 1 or 0 in all body regions. RESULTS: Of 1345 children followed for median (IQR) 5.5 (2.9, 8.2) years after ART initiation, 30 developed LA and 27 developed LH, all at least 2 years after ART initiation. Median age at LA diagnosis was 11 (10, 13) years and at LH diagnosis was 13 (11, 15) years. Children with LA were more likely white (p<0.0001); lower height-for-age z-score at ART initiation (p = 0.02); initiated ART earlier (p = 0.04), with longer ART exposure (p = 0.04). Children with LH were similar to those without. Analysis of individual drugs revealed that LA was associated with greater duration of exposure to stavudine and didanosine; while LH was associated with greater duration of exposure to stavudine and ritonavir (given alone or in combination with another protease inhibitor). Median time in follow-up following ART switch was 2.8 (1.9, 4.9) and 2.5 (1.6, 4.7) years respectively. Resolution occurred in 10 (30%) of LA cases (median time to resolution 2.3 [1.8, 3.6] years) and 3 (11%) of LH cases (median time to resolution 2.0 [1.7, 2.1] years). CONCLUSIONS: Prevalence of LA and LH were low, with some resolution noted, especially for LA. More long-term data are needed.
format Online
Article
Text
id pubmed-5884482
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-58844822018-04-13 Lipoatrophy/lipohypertrophy outcomes after antiretroviral therapy switch in children in the UK/Ireland Innes, Steve Harvey, Justin Collins, Intira Jeannie Cotton, Mark Fredric Judd, Ali PLoS One Research Article BACKGROUND: Following widespread use of stavudine, a thymidine analogue, in antiretroviral therapy (ART) over the past three decades, up to a third of children developed lipoatrophy (LA) and/or lipohypertrophy (LH). Following phasing-out of stavudine, incidence of newly-diagnosed LA and LH declined dramatically. However, the natural history of existing cases should be explored, particularly with prolonged protease inhibitor exposure. METHODS: The Collaborative HIV Paediatric Study (CHIPS) is a multicentre cohort study of most HIV-infected children in the United Kingdom and Ireland. Those on ART with a LA/LH assessment recorded in 2003–2011 were included. Assessments were completed annually by consultant physicians. Using the 0–3 grading system, LA or LH was defined as grade 2 or 3. Resolution was defined as return to grade 1 or 0 in all body regions. RESULTS: Of 1345 children followed for median (IQR) 5.5 (2.9, 8.2) years after ART initiation, 30 developed LA and 27 developed LH, all at least 2 years after ART initiation. Median age at LA diagnosis was 11 (10, 13) years and at LH diagnosis was 13 (11, 15) years. Children with LA were more likely white (p<0.0001); lower height-for-age z-score at ART initiation (p = 0.02); initiated ART earlier (p = 0.04), with longer ART exposure (p = 0.04). Children with LH were similar to those without. Analysis of individual drugs revealed that LA was associated with greater duration of exposure to stavudine and didanosine; while LH was associated with greater duration of exposure to stavudine and ritonavir (given alone or in combination with another protease inhibitor). Median time in follow-up following ART switch was 2.8 (1.9, 4.9) and 2.5 (1.6, 4.7) years respectively. Resolution occurred in 10 (30%) of LA cases (median time to resolution 2.3 [1.8, 3.6] years) and 3 (11%) of LH cases (median time to resolution 2.0 [1.7, 2.1] years). CONCLUSIONS: Prevalence of LA and LH were low, with some resolution noted, especially for LA. More long-term data are needed. Public Library of Science 2018-04-04 /pmc/articles/PMC5884482/ /pubmed/29617438 http://dx.doi.org/10.1371/journal.pone.0194132 Text en © 2018 Innes et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Innes, Steve
Harvey, Justin
Collins, Intira Jeannie
Cotton, Mark Fredric
Judd, Ali
Lipoatrophy/lipohypertrophy outcomes after antiretroviral therapy switch in children in the UK/Ireland
title Lipoatrophy/lipohypertrophy outcomes after antiretroviral therapy switch in children in the UK/Ireland
title_full Lipoatrophy/lipohypertrophy outcomes after antiretroviral therapy switch in children in the UK/Ireland
title_fullStr Lipoatrophy/lipohypertrophy outcomes after antiretroviral therapy switch in children in the UK/Ireland
title_full_unstemmed Lipoatrophy/lipohypertrophy outcomes after antiretroviral therapy switch in children in the UK/Ireland
title_short Lipoatrophy/lipohypertrophy outcomes after antiretroviral therapy switch in children in the UK/Ireland
title_sort lipoatrophy/lipohypertrophy outcomes after antiretroviral therapy switch in children in the uk/ireland
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884482/
https://www.ncbi.nlm.nih.gov/pubmed/29617438
http://dx.doi.org/10.1371/journal.pone.0194132
work_keys_str_mv AT innessteve lipoatrophylipohypertrophyoutcomesafterantiretroviraltherapyswitchinchildrenintheukireland
AT harveyjustin lipoatrophylipohypertrophyoutcomesafterantiretroviraltherapyswitchinchildrenintheukireland
AT collinsintirajeannie lipoatrophylipohypertrophyoutcomesafterantiretroviraltherapyswitchinchildrenintheukireland
AT cottonmarkfredric lipoatrophylipohypertrophyoutcomesafterantiretroviraltherapyswitchinchildrenintheukireland
AT juddali lipoatrophylipohypertrophyoutcomesafterantiretroviraltherapyswitchinchildrenintheukireland